和黄医药今日宣布，其创新药物索乐普尼针对温抗体自身免疫性溶血性贫血在中国开展的ESLIM-02试验III期阶段取得积极的顶线结果。
该研究达到了预设的主要疗效终点，数据显示索乐普尼治疗组在关键指标上表现出具有统计学显著性和临床意义的改善。安全性方面，索乐普尼的表现与既往研究数据一致，未发现新的安全性信号。
这一积极成果标志着索乐普尼在治疗这一罕见血液疾病方面迈出了关键一步，为后续向监管机构提交上市申请奠定了坚实基础。
和黄医药今日宣布，其创新药物索乐普尼针对温抗体自身免疫性溶血性贫血在中国开展的ESLIM-02试验III期阶段取得积极的顶线结果。
该研究达到了预设的主要疗效终点，数据显示索乐普尼治疗组在关键指标上表现出具有统计学显著性和临床意义的改善。安全性方面，索乐普尼的表现与既往研究数据一致，未发现新的安全性信号。
这一积极成果标志着索乐普尼在治疗这一罕见血液疾病方面迈出了关键一步，为后续向监管机构提交上市申请奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.